Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buagafuran for Generalized Anxiety Disorder
NCT06243614Phase 3Recruiting
- Sponsor
- Beijing Union Pharmaceutical Factory
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buagafuran in generalized anxiety disorder (GAD) (3 arms), sponsored by Beijing Union Pharmaceutical Factory. Primary endpoint: Change in Hamilton anxiety scale score at 8 weeks. Started Jul 2023; status: recruiting.
02
Drugs
buagafuran
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06243614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06243614.